Vector-Borne Diseases & Gene Drive
Ethics Grand Rounds:
- Do we have the moral right to alter ecosystems?
- How do we deal with non-consensual communities or individuals in a field trial context, how do we engage with communities regarding this technology?
- How do deal with reparations if a field trial goes wrong, etc.
Jerome Singh, BA, LLB, LLM, PhD, MHSc, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal (UKZN); Joint Center for Bioethics, University of Toronto | Professor Singh is the Director of the Ethical, Legal, and Social Issues (ELSI) Advisory Services on Global Health Research and Development and serves as an ad hoc Consultant to several UN entities, including the WHO, UNAIDS, UNICEF, the Special Programme for Research and Training in Tropical Diseases (WHO-TDR), and the United Nations Interregional Crime and Justice Research Institute (UNICRI). He is the Co-Chairperson of the NIH-sponsored HIV Prevention Trial Network’s (HPTN) Ethics Working Group, and a member of the NIH-sponsored HIV Vaccine Trial Network’s (HVTN) Efficacy Trial Working Group. He currently serves on several oversight bodies, including the International Ethics Review Board of Médecins Sans Frontières (MSF) and the World Health Organisation’s Ad Hoc Research Ethics Review Committee for COVID-19.